Company: HRTX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-028374
Chunk: 114

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-02-27
Form: 10-K
Item: Item 1B
Chunk 114
---
 Gross profit

    105,637

    61,939

    52,798

    Operating expenses:

    Research and development

    16,683

    39,133

    82,704

    General and administrative

    53,397

    65,778

    62,239

    Sales and marketing

    47,085

    67,643

    82,513

    Total operating expenses

    117,165

    172,554

    227,456

    Loss from operations

    (11,528
    )

    (110,615
    )

    (174,658
    )

    Other (expense) income, net:

    Interest income

    3,550

    3,364

    1,638

    Interest expense

    (6,032
    )

    (3,868
    )

    (2,474
    )

    Other income (expense)

    430

    560

    (6,530
    )

    Total other (expense) income, net

    (2,052
    )

    56

    (7,366
    )

    Net loss

    (13,580
    )

    (110,559
    )

    (182,024
    )

    Other comprehensive income (loss):

    Unrealized gains (losses) on short-term investments

    -

    32

    (13
    )

    Comprehensive loss
     
    $
    (13,580
    )
     
    $
    (110,527
    )
     
    $
    (182,037
    )

    Basic and diluted net loss per share
     
    $
    (0.09
    )
     
    $
    (0.80
    )
     
    $
    (1.67
    )

    Shares used in computing basic and diluted net loss per share

    152,449

    138,135

    108,876

See accompanying Notes to Consolidated Financial Statements.

75

HERON THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(In thousands)

    Accumulated

    Additional

    Other

    Total

    Common Stock

    Paid-In

    Comprehensive

    Accumulated

    Stockholders’

    Shares